DM
Insider
David Scott Moore
DirectorDavid Scott Moore (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Corvus Pharmaceuticals, Inc. (CRVS). Across 1 priced purchase filing, the average 21-session return was +31.6% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $250K of CRVS (21,700 sh × $11.53, as filed), executed Jun 11.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+31.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+24.2%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$250K
shares × price, as filed
Last traded
Jun 11
Filed Jun 15
Median ADV $19.4M across their filed names
Open performance→Volume by month
Buys $250K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
CRVSRecent filings
CRVSPURCHASE
Corvus Pharmaceuticals, Inc.
View filing →
$250K21,700 sh × $11.53
Exec Jun 11
Filed Jun 15 · 5:12 PM ET